 Ruofei Du
Concepts (182)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pregnant Women | 2 | 2023 | 77 | 0.890 |
Why?
| | Metagenomics | 3 | 2015 | 38 | 0.680 |
Why?
| | Papillomavirus Infections | 4 | 2023 | 155 | 0.670 |
Why?
| | Pregnancy Complications | 1 | 2023 | 382 | 0.670 |
Why?
| | Uterine Cervical Dysplasia | 3 | 2023 | 49 | 0.580 |
Why?
| | Uterine Cervical Neoplasms | 3 | 2023 | 277 | 0.520 |
Why?
| | Sequence Homology, Nucleic Acid | 1 | 2013 | 48 | 0.440 |
Why?
| | DNA Replication | 2 | 2024 | 150 | 0.430 |
Why?
| | Sequence Analysis, DNA | 1 | 2013 | 237 | 0.410 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2013 | 169 | 0.400 |
Why?
| | Arsenic | 2 | 2021 | 24 | 0.350 |
Why?
| | Early Detection of Cancer | 5 | 2023 | 169 | 0.340 |
Why?
| | DNA Ligases | 2 | 2024 | 4 | 0.300 |
Why?
| | Genetic Counseling | 2 | 2017 | 38 | 0.280 |
Why?
| | Phthalazines | 1 | 2024 | 20 | 0.240 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2024 | 30 | 0.240 |
Why?
| | Cervix Uteri | 2 | 2023 | 49 | 0.240 |
Why?
| | Piperazines | 1 | 2024 | 117 | 0.230 |
Why?
| | Mass Screening | 3 | 2023 | 353 | 0.220 |
Why?
| | Morbidity | 1 | 2023 | 133 | 0.220 |
Why?
| | Proliferating Cell Nuclear Antigen | 1 | 2023 | 75 | 0.220 |
Why?
| | Humans | 25 | 2023 | 49974 | 0.220 |
Why?
| | Pregnancy | 4 | 2023 | 2607 | 0.210 |
Why?
| | Prenatal Exposure Delayed Effects | 2 | 2021 | 186 | 0.200 |
Why?
| | New Mexico | 4 | 2023 | 13 | 0.200 |
Why?
| | Comorbidity | 1 | 2023 | 615 | 0.200 |
Why?
| | Radiation Protection | 1 | 2021 | 47 | 0.200 |
Why?
| | Female | 14 | 2023 | 26472 | 0.190 |
Why?
| | Breast Neoplasms | 3 | 2020 | 1174 | 0.190 |
Why?
| | Medicaid | 1 | 2023 | 257 | 0.190 |
Why?
| | Precancerous Conditions | 1 | 2021 | 83 | 0.190 |
Why?
| | Histones | 1 | 2023 | 312 | 0.190 |
Why?
| | United States | 4 | 2023 | 4860 | 0.180 |
Why?
| | Prevalence | 1 | 2023 | 944 | 0.180 |
Why?
| | Medically Underserved Area | 1 | 2020 | 42 | 0.180 |
Why?
| | Mammography | 1 | 2020 | 96 | 0.180 |
Why?
| | Telephone | 2 | 2017 | 70 | 0.170 |
Why?
| | Nutrition Surveys | 1 | 2020 | 104 | 0.170 |
Why?
| | Maternal Nutritional Physiological Phenomena | 1 | 2020 | 57 | 0.170 |
Why?
| | Nutritional Status | 1 | 2020 | 141 | 0.160 |
Why?
| | Prostatic Neoplasms | 1 | 2023 | 394 | 0.160 |
Why?
| | Receptor, Nerve Growth Factor | 1 | 2018 | 2 | 0.160 |
Why?
| | Thrombosis | 1 | 2021 | 248 | 0.160 |
Why?
| | alpha-Synuclein | 1 | 2018 | 10 | 0.160 |
Why?
| | Parkinsonian Disorders | 1 | 2018 | 10 | 0.160 |
Why?
| | Neoplasms | 2 | 2022 | 1235 | 0.160 |
Why?
| | Uranium | 1 | 2018 | 1 | 0.160 |
Why?
| | Ubiquitination | 1 | 2018 | 43 | 0.160 |
Why?
| | Developmental Disabilities | 1 | 2019 | 119 | 0.160 |
Why?
| | Papillomaviridae | 3 | 2023 | 102 | 0.150 |
Why?
| | Pluripotent Stem Cells | 1 | 2017 | 6 | 0.150 |
Why?
| | GABAergic Neurons | 1 | 2017 | 10 | 0.150 |
Why?
| | Zinc | 1 | 2018 | 53 | 0.150 |
Why?
| | Organoplatinum Compounds | 1 | 2017 | 14 | 0.150 |
Why?
| | Neurogenesis | 1 | 2017 | 27 | 0.150 |
Why?
| | Deoxycytidine | 1 | 2017 | 27 | 0.150 |
Why?
| | Bile Duct Neoplasms | 1 | 2017 | 29 | 0.150 |
Why?
| | Pandemics | 1 | 2022 | 559 | 0.150 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2017 | 138 | 0.140 |
Why?
| | Environmental Pollutants | 1 | 2018 | 91 | 0.140 |
Why?
| | Genetic Testing | 1 | 2017 | 119 | 0.140 |
Why?
| | Genes, BRCA2 | 1 | 2016 | 12 | 0.140 |
Why?
| | Genes, BRCA1 | 1 | 2016 | 19 | 0.140 |
Why?
| | Ovarian Neoplasms | 2 | 2017 | 447 | 0.140 |
Why?
| | Papillomavirus Vaccines | 1 | 2017 | 61 | 0.140 |
Why?
| | Diet | 1 | 2020 | 566 | 0.130 |
Why?
| | Adult | 9 | 2022 | 13236 | 0.130 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2017 | 191 | 0.120 |
Why?
| | Genes, Bacterial | 1 | 2014 | 64 | 0.120 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2014 | 53 | 0.120 |
Why?
| | Data Interpretation, Statistical | 1 | 2014 | 158 | 0.110 |
Why?
| | Mutation | 2 | 2017 | 1294 | 0.110 |
Why?
| | Young Adult | 5 | 2022 | 3958 | 0.110 |
Why?
| | Liver Neoplasms | 1 | 2017 | 326 | 0.110 |
Why?
| | Oxidative Stress | 1 | 2018 | 770 | 0.110 |
Why?
| | Chromatin | 2 | 2024 | 151 | 0.110 |
Why?
| | Databases, Genetic | 1 | 2013 | 88 | 0.110 |
Why?
| | Genome, Human | 1 | 2013 | 111 | 0.100 |
Why?
| | Seroepidemiologic Studies | 2 | 2022 | 43 | 0.100 |
Why?
| | Evolution, Molecular | 1 | 2013 | 99 | 0.100 |
Why?
| | Adolescent | 5 | 2022 | 6356 | 0.100 |
Why?
| | Cohort Studies | 3 | 2022 | 1422 | 0.100 |
Why?
| | Statistics, Nonparametric | 1 | 2012 | 194 | 0.100 |
Why?
| | DNA | 2 | 2024 | 541 | 0.090 |
Why?
| | Computational Biology | 1 | 2012 | 214 | 0.090 |
Why?
| | Middle Aged | 6 | 2022 | 12069 | 0.090 |
Why?
| | MicroRNAs | 1 | 2013 | 353 | 0.080 |
Why?
| | Child Development | 2 | 2021 | 190 | 0.080 |
Why?
| | Infant | 3 | 2022 | 3567 | 0.080 |
Why?
| | Mice | 3 | 2024 | 5739 | 0.080 |
Why?
| | Gene Expression Profiling | 1 | 2012 | 1032 | 0.070 |
Why?
| | Animals | 4 | 2024 | 13187 | 0.070 |
Why?
| | Registries | 2 | 2021 | 522 | 0.070 |
Why?
| | Retrospective Studies | 3 | 2023 | 6108 | 0.070 |
Why?
| | Obesity | 1 | 2014 | 1113 | 0.070 |
Why?
| | Child, Preschool | 2 | 2022 | 3871 | 0.060 |
Why?
| | DNA Polymerase III | 1 | 2023 | 5 | 0.060 |
Why?
| | Human papillomavirus 16 | 1 | 2023 | 44 | 0.060 |
Why?
| | Vaginal Smears | 1 | 2023 | 28 | 0.060 |
Why?
| | Facial Expression | 1 | 2022 | 14 | 0.050 |
Why?
| | Cross-Cultural Comparison | 1 | 2022 | 26 | 0.050 |
Why?
| | Models, Statistical | 2 | 2015 | 224 | 0.050 |
Why?
| | Eye Movements | 1 | 2022 | 26 | 0.050 |
Why?
| | Prostate | 1 | 2023 | 117 | 0.050 |
Why?
| | Genotype | 1 | 2023 | 537 | 0.050 |
Why?
| | Employment | 1 | 2022 | 90 | 0.050 |
Why?
| | Antibodies, Viral | 1 | 2022 | 88 | 0.050 |
Why?
| | Antigens, Neoplasm | 1 | 2023 | 151 | 0.050 |
Why?
| | Lead | 1 | 2021 | 33 | 0.050 |
Why?
| | Survivors | 1 | 2022 | 126 | 0.050 |
Why?
| | Platelet Glycoprotein GPIb-IX Complex | 1 | 2021 | 49 | 0.050 |
Why?
| | Cell Line | 1 | 2024 | 1000 | 0.050 |
Why?
| | Minority Groups | 1 | 2022 | 132 | 0.050 |
Why?
| | Aged | 3 | 2022 | 9310 | 0.050 |
Why?
| | Maternal Exposure | 1 | 2021 | 86 | 0.050 |
Why?
| | Emotions | 1 | 2022 | 165 | 0.050 |
Why?
| | Mexico | 1 | 2020 | 36 | 0.050 |
Why?
| | Electronic Health Records | 1 | 2022 | 209 | 0.050 |
Why?
| | Breast | 1 | 2020 | 85 | 0.040 |
Why?
| | Protein Binding | 1 | 2021 | 660 | 0.040 |
Why?
| | Interviews as Topic | 1 | 2020 | 259 | 0.040 |
Why?
| | Problem Solving | 1 | 2019 | 43 | 0.040 |
Why?
| | Bayes Theorem | 1 | 2019 | 109 | 0.040 |
Why?
| | Mothers | 1 | 2021 | 249 | 0.040 |
Why?
| | Psychomotor Performance | 1 | 2019 | 130 | 0.040 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2023 | 614 | 0.040 |
Why?
| | Rotenone | 1 | 2018 | 14 | 0.040 |
Why?
| | Transcription Factor RelA | 1 | 2018 | 29 | 0.040 |
Why?
| | Dopaminergic Neurons | 1 | 2018 | 18 | 0.040 |
Why?
| | Qualitative Research | 1 | 2020 | 329 | 0.040 |
Why?
| | Psychometrics | 1 | 2019 | 224 | 0.040 |
Why?
| | COUP Transcription Factor II | 1 | 2017 | 1 | 0.040 |
Why?
| | Indians, North American | 1 | 2018 | 35 | 0.040 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2018 | 92 | 0.040 |
Why?
| | BRCA2 Protein | 1 | 2017 | 15 | 0.040 |
Why?
| | Predictive Value of Tests | 1 | 2020 | 903 | 0.040 |
Why?
| | Random Allocation | 1 | 2018 | 281 | 0.040 |
Why?
| | BRCA1 Protein | 1 | 2017 | 31 | 0.040 |
Why?
| | Inflammation | 1 | 2021 | 604 | 0.040 |
Why?
| | Communication | 1 | 2019 | 246 | 0.040 |
Why?
| | Health Expenditures | 1 | 2017 | 67 | 0.040 |
Why?
| | Age Distribution | 1 | 2017 | 168 | 0.040 |
Why?
| | Sensitivity and Specificity | 1 | 2019 | 861 | 0.040 |
Why?
| | Socioeconomic Factors | 1 | 2019 | 581 | 0.040 |
Why?
| | Glutamic Acid | 1 | 2017 | 107 | 0.040 |
Why?
| | Cross-Sectional Studies | 1 | 2022 | 1557 | 0.040 |
Why?
| | Nuclear Proteins | 1 | 2018 | 242 | 0.040 |
Why?
| | Insurance, Health | 1 | 2017 | 126 | 0.030 |
Why?
| | Environmental Exposure | 1 | 2018 | 199 | 0.030 |
Why?
| | Parents | 1 | 2019 | 314 | 0.030 |
Why?
| | Mice, Inbred C57BL | 1 | 2021 | 1816 | 0.030 |
Why?
| | Arkansas | 1 | 2022 | 1977 | 0.030 |
Why?
| | Patient-Centered Care | 1 | 2017 | 129 | 0.030 |
Why?
| | Male | 3 | 2023 | 25241 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2019 | 1193 | 0.030 |
Why?
| | Survival Analysis | 1 | 2017 | 653 | 0.030 |
Why?
| | Transcriptome | 1 | 2017 | 315 | 0.030 |
Why?
| | Mucus | 1 | 2014 | 4 | 0.030 |
Why?
| | Saliva | 1 | 2014 | 54 | 0.030 |
Why?
| | Rats, Sprague-Dawley | 1 | 2018 | 1597 | 0.030 |
Why?
| | Cell Line, Tumor | 1 | 2018 | 1403 | 0.030 |
Why?
| | ROC Curve | 1 | 2014 | 232 | 0.030 |
Why?
| | Incidence | 1 | 2017 | 1003 | 0.030 |
Why?
| | Cells, Cultured | 1 | 2017 | 1573 | 0.030 |
Why?
| | Gastrointestinal Tract | 1 | 2014 | 103 | 0.030 |
Why?
| | Gene Expression Regulation | 1 | 2018 | 976 | 0.030 |
Why?
| | RNA Precursors | 1 | 2013 | 9 | 0.030 |
Why?
| | Gene Expression Regulation, Bacterial | 1 | 2014 | 191 | 0.030 |
Why?
| | Apoptosis | 1 | 2018 | 1101 | 0.030 |
Why?
| | Nucleic Acid Conformation | 1 | 2013 | 83 | 0.030 |
Why?
| | Chromosome Mapping | 1 | 2013 | 156 | 0.030 |
Why?
| | Models, Genetic | 1 | 2013 | 170 | 0.030 |
Why?
| | Sample Size | 1 | 2012 | 37 | 0.030 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 989 | 0.020 |
Why?
| | Prospective Studies | 1 | 2017 | 2364 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2014 | 1131 | 0.020 |
Why?
| | Computer Simulation | 1 | 2012 | 280 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2016 | 2182 | 0.020 |
Why?
| | Child | 1 | 2022 | 6847 | 0.020 |
Why?
| | Research Design | 1 | 2012 | 344 | 0.020 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2015 | 477 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2017 | 5141 | 0.020 |
Why?
|
|
Du's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|